ClinicalTrials.gg
Sign In

Drug

Anti-TIM-3 Monoclonal Antibody TQB2618 clinical trials

studies test it
9
open now
1
in phase 3
0
first study started
2020

Keep track of what changes. Save the Anti-TIM-3 Monoclonal Antibody TQB2618 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

TQB2618 injection
4

Combined with it in one product

TQB2618 injection; Penpulimab injection
1
TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin
1
TQB2618 injection and TQB2450 injection
1

Studies by the year they started

9 studies that test it; most in 2022 (5)

Studies that test Anti-TIM-3 Monoclonal Antibody TQB2618, by start year
YearStudies
20201
20225
20233

By phase

A phase 1/2 study counts in both.

Phase 1
8
Phase 2
5

What it is tested for

Each study’s main condition, where its own words name it.

Neoplasms
2
Nasopharyngeal Carcinoma
1
Squamous Cell Carcinoma of Head and Neck
1
Melanoma
1
Lymphoma
1
Leukemia, Myeloid, Acute
1

Who runs them

Industry 9 · Other 0

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (9)

Often tested with

Tested in the same studies.

Penpulimab (4) · Catequentinib hydrochloride (1) · Paclitaxel (1) · Cisplatin (1) · Toripalimab (1) · Benmelstobart (1)

Studies

Open first, then newest update. How each study uses Anti-TIM-3 Monoclonal Antibody TQB2618 is read from its arms, and is right about nine times in ten.

Testing it · 9

Given in every arm · 1 — Anti-TIM-3 Monoclonal Antibody TQB2618 is usual care beside what is tested